Cantor Fitzgerald Comments on Disc Medicine FY2026 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Disc Medicine in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will earn ($5.46) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $132.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Several other equities research analysts have also recently weighed in on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. TD Cowen initiated coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Raymond James began coverage on Disc Medicine in a research report on Wednesday. They set a “strong-buy” rating and a $89.00 price target on the stock. Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, March 3rd. Finally, BMO Capital Markets raised their price objective on Disc Medicine from $112.00 to $120.00 and gave the stock an “outperform” rating in a research report on Monday, May 12th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $96.70.

Disc Medicine Stock Performance

Shares of IRON opened at $50.86 on Tuesday. The company has a 50 day moving average price of $45.20 and a 200-day moving average price of $53.48. Disc Medicine has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The stock has a market capitalization of $1.76 billion, a PE ratio of -12.78 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Insiders Place Their Bets

In related news, Director Mona Ashiya sold 10,011 shares of the company’s stock in a transaction on Friday, March 21st. The stock was sold at an average price of $54.00, for a total value of $540,594.00. Following the transaction, the director now directly owns 187,297 shares of the company’s stock, valued at $10,114,038. This represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Jacob Savage sold 2,996 shares of the company’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $50.00, for a total value of $149,800.00. Following the completion of the transaction, the insider now directly owns 56,725 shares in the company, valued at approximately $2,836,250. The trade was a 5.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,178 shares of company stock valued at $3,582,568. Insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new stake in shares of Disc Medicine during the fourth quarter worth about $5,479,000. Barclays PLC lifted its holdings in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock worth $1,972,000 after purchasing an additional 22,202 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Disc Medicine during the fourth quarter worth about $335,000. Deutsche Bank AG increased its stake in shares of Disc Medicine by 75.7% in the fourth quarter. Deutsche Bank AG now owns 16,093 shares of the company’s stock worth $1,020,000 after acquiring an additional 6,933 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Disc Medicine in the fourth quarter worth $5,579,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.